Neuland Laboratories, the Hyderabad-based pharmaceutical manufacturer supplying APIs, complex intermediates, and custom manufacturing solutions to around 80 countries, has announced its financial results for the nine months ended Dec 31, 2025.

 

Neuland posted a total income of Rs. 1,264.5 crore, with EBITDA of Rs. 284 crore.

 

Commenting on the results, Sucheth Davuluri, Vice-Chairman and CEO, said, “The revenues this quarter are in line with the outlook we envisaged for the year, however the product mix within businesses as well as increased operating expenses is reflected in subdued EBITDA margins. We continue to see good momentum in the business which is driving our investments with the long-term in view, ensuring Neuland can take advantage of the number of growth opportunities.”

 

Saharsh Davuluri, Vice Chairman and Managing Director, added, “We are seeing increasing interest from a wider range of customers interested in our capabilities as a proven commercial NCE drug substance manufacturer as well as an integral partner in the innovation journey. Our investments are leading to more engagements with existing customers while also attracting new customers who are looking for specific niche capabilities.”

 

Quarterly performance (Q3FY26 vs Q3FY25) stands as follows: Total Income: Rs. 447.8 crore, up 11.4% YoY (Q2FY26: Rs. 516.1 crore, down 13.2% QoQ); EBITDA: Rs. 85.0 crore, down 5.9% YoY (Q2FY26: Rs. 156.9 crore, down 45.8% QoQ); Profit Before Tax: Rs. 54.3 crore, down 57.4% YoY; Profit After Tax: Rs. 40.4 crore, down 60.2% YoY.

 

The company noted that increased operating expenses and a shift in product mix contributed to lower margins, while long-term investments continue to drive business momentum and customer engagement.